NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) has put INGREZZA back in focus after publishing KINECT-PRO Phase 4 results that link once-daily treatment with sustained improvements in tardive dyskinesia symptoms and patient-reported quality of life in real-world settings.
See our latest analysis for Neurocrine Biosciences.
The INGREZZA data arrives after a mixed trading patch for Neurocrine Biosciences, with the share price down 9.6% over 30 days but still showing a 9.9% year to date share price return and a...